1. Scrip

Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership

Korean Phase II/III Study To Begin Soon

 
• By Jung Won Shin

Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.

partnership
Co-development With Shionogi To Expand To Manufacturing, Supply In Korea • Source: Alamy

Ildong Pharmaceutical Co., Ltd. has joined hands with Shionogi & Co. Ltd. to develop in South Korea the Japanese company's oral antiviral candidate for COVID-19, S-217622.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia